Home / Innere Medizin / Onkologie / ASH 2019: „Kongress-Daten werden klinische Praxis bei AML/MDS ändern“

Univ.-Prof. Dr. Michael Pfeilstöcker

ASH 2019: „Kongress-Daten werden klinische Praxis bei AML/MDS ändern“

Univ.-Prof. Dr. Michael Pfeilstöcker, 3. Medizinische Abteilung, Hanusch Krankenhaus Wien, erklärt, was MDS/AML-Interessierte beim ASH nicht verpassen dürfen. Neben spannenden Studien zu Erhaltungstherapie, Whole Genome Sequenzing und Graft-vs.-Host-Disease(GvHD)-Prophylaxe, ist die Immuntherapie ein großes Thema.

Cookies aktivieren

Um das Video anzusehen, müssen Sie Statistikcookies akzeptieren.

Einstellungen verwalten

Univ.-Prof. Dr. Michael Pfeilstöcker, 3. Medizinische Abteilung, Hanusch Krankenhaus Wien, erklärt, was MDS/AML-Interessierte beim ASH nicht verpassen dürfen. Neben spannenden Studien zu Erhaltungstherapie, Whole Genome Sequenzing und Graft-vs.-Host (GvDH)-Prophylaxe, ist die Immuntherapie ein großes Thema.

Quelle: ASH Annual Meeting 2019

Abstracts, die im Video erwähnt werden:

Iacobucci I et al., Abstract LBA-4
https://ash.confex.com/ash/2019/webprogram/Paper132746.html

Wei AH et al., Abstract LBA-3
LBA-3 The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
https://ash.confex.com/ash/2019/webprogram/Paper132405.html

Sallman DA et al., Abstract 569
569 The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
https://ash.confex.com/ash/2019/webprogram/Paper126271.html

Garcia-Manero G et al., Abstract 4243
4243 Hematologic Improvement–Neutrophil and –Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
https://ash.confex.com/ash/2019/webprogram/Paper123048.html

Fenaux P et al., Abstract 841
841 Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
https://ash.confex.com/ash/2019/webprogram/Paper123064.html

Platzbecker U et al., Abstract 2999
2999 Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial
https://ash.confex.com/ash/2019/webprogram/Paper123655.html

Sallman D et al., Abstract 676
676 Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
https://ash.confex.com/ash/2019/webprogram/Paper131055.html

Cluzeau T et al., Abstract 677
677 APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)
https://ash.confex.com/ash/2019/webprogram/Paper125579.html

De Jong CN et al., Abstract 1
Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors
https://ash.confex.com/ash/2019/webprogram/Paper124659.html

Jetzt für unsere Newsletter anmelden!

In unseren Newslettern informieren wir Sie regelmäßig über Neuigkeiten aus der Welt der Medizin, neue Fortbildungen und fachspezifische Inhalte.

LOGIN